{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T07:50:39Z","timestamp":1772783439910,"version":"3.50.1"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.jconrel.2018.10.017","type":"journal-article","created":{"date-parts":[[2018,10,17]],"date-time":"2018-10-17T19:51:32Z","timestamp":1539805892000},"page":"80-89","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Successful intracranial delivery of trastuzumab by gene-therapy for treatment of HER2-positive breast cancer brain metastases"],"prefix":"10.1016","volume":"291","author":[{"given":"Inbal","family":"Zafir-Lavie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shay","family":"Sherbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haim","family":"Goltsman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Badinter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eilam","family":"Yeini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Ofek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reem","family":"Miari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osnat","family":"Tal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atar","family":"Liran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamar","family":"Shatil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simi","family":"Krispel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nir","family":"Shapir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Garry A.","family":"Neil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0824-7177","authenticated-orcid":false,"given":"Itai","family":"Benhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amos","family":"Panet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronit","family":"Satchi-Fainaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2018.10.017_bb0005","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4161\/19420862.2015.989042","article-title":"The therapeutic monoclonal antibody market","volume":"7","author":"Ecker","year":"2015","journal-title":"MAbs"},{"key":"10.1016\/j.jconrel.2018.10.017_bb0010","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1200\/JCO.2008.19.9844","article-title":"Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review","volume":"28","author":"Dawood","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2018.10.017_bb0015","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2018.10.017_bb0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0021030","article-title":"Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: a meta-analysis of published randomized controlled trials","volume":"6","author":"Yin","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jconrel.2018.10.017_bb0025","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1002\/1097-0142(19831215)52:12<2349::AID-CNCR2820521231>3.0.CO;2-B","article-title":"Central nervous system metastasis from breast carcinoma. Autopsy study","volume":"52","author":"Tsukada","year":"1983","journal-title":"Cancer"},{"key":"10.1016\/j.jconrel.2018.10.017_bb0030","doi-asserted-by":"crossref","first-page":"3608","DOI":"10.1200\/JCO.2004.01.175","article-title":"CNS metastases in breast cancer","volume":"22","author":"Lin","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2018.10.017_bb0035","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2165\/00023210-200721070-00003","article-title":"CNS complications of breast cancer: current and emerging treatment options","volume":"21","author":"Kaal","year":"2007","journal-title":"CNS drugs"},{"key":"10.1016\/j.jconrel.2018.10.017_bb0040","series-title":"Incidence, Pattern and Timing of Brain Metastases Among Patients with Advanced Breast Cancer Treated with Trastuzumab, Acta Oncologica (Stockholm, Sweden)","first-page":"196","volume":"45","author":"Yau","year":"2006"},{"key":"10.1016\/j.jconrel.2018.10.017_bb0045","series-title":"Proceedings of the National Academy of Sciences of the United States of America","first-page":"5705","article-title":"Macromolecular permeability across the blood-nerve and blood-brain barriers","volume":"Vol. 91","author":"Poduslo","year":"1994"},{"key":"10.1016\/j.jconrel.2018.10.017_bb0050","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1200\/JCO.2000.18.11.2349","article-title":"Trastuzumab in CSF","volume":"18","author":"Pestalozzi","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2018.10.017_bb0055","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002716","article-title":"Hematopoietic stem cell gene therapy for adenosine deaminase\u2013deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction","volume":"3","author":"Gaspar","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2018.10.017_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.joco.2018.01.006","article-title":"Prospect of retinal gene therapy following commercialization of voretigene neparvovec-rzyl for retinal dystrophy mediated by RPE65 mutation","volume":"30","author":"Ameri","year":"2018","journal-title":"J. Curr. Ophthalmol."},{"key":"10.1016\/j.jconrel.2018.10.017_bb0065","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1089\/hgtb.2018.038","article-title":"Assessment of humoral, innate, and T-cell immune responses to adeno-associated virus vectors","volume":"2","author":"Calcedo","year":"2018","journal-title":"Human Gene Therap. Method"},{"key":"10.1016\/j.jconrel.2018.10.017_bb0070","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1056\/NEJMoa1700554","article-title":"Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy","volume":"377","author":"Eichler","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2018.10.017_bb0075","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nature22395","article-title":"Therapeutic T cell engineering","volume":"545","author":"Sadelain","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2018.10.017_bb0080","series-title":"Tisagenlecleucel, an approved anti-CD19 chimeric antigen receptor T-cell therapy for the treatment of leukemia, drugs of today (Barcelona, Spain: 1998)","first-page":"597","volume":"53","author":"Liu","year":"2017"},{"key":"10.1016\/j.jconrel.2018.10.017_bb0085","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nrclinonc.2018.11","article-title":"Approvals in 2017: gene therapies and site-agnostic indications","volume":"15","author":"Blumenthal","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2018.10.017_bb0090","first-page":"1","article-title":"Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL","author":"Roberts","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.jconrel.2018.10.017_bb0095","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/cts.12466","article-title":"Gene therapy 2017: progress and future directions","volume":"10","author":"Keeler","year":"2017","journal-title":"Clin. Transl. Sci."},{"issue":"Suppl. 5","key":"10.1016\/j.jconrel.2018.10.017_bb0100","first-page":"001","article-title":"Helper-dependent adenoviral vectors","author":"Rosewell","year":"2011","journal-title":"J. Gen. Syndr. Gene Therap."},{"key":"10.1016\/j.jconrel.2018.10.017_bb0105","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.3390\/v2091886","article-title":"Gene therapy with helper-dependent adenoviral vectors: current advances and future perspectives","volume":"2","author":"Vetrini","year":"2010","journal-title":"Viruses"},{"key":"10.1016\/j.jconrel.2018.10.017_bb0110","doi-asserted-by":"crossref","first-page":"589","DOI":"10.18388\/abp.2005_3419","article-title":"Helper-dependent adenoviral vectors in experimental gene therapy","volume":"52","author":"Jozkowicz","year":"2005","journal-title":"Acta Biochim. Pol."},{"key":"10.1016\/j.jconrel.2018.10.017_bb0115","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1056\/NEJMc1606202","article-title":"TARGT gene therapy platform for correction of anemia in end-stage renal disease","volume":"376","author":"Blum","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2018.10.017_bb0120","doi-asserted-by":"crossref","DOI":"10.1002\/jgm.2965","article-title":"Sustained secretion of anti-tumor necrosis factor alpha monoclonal antibody from ex vivo genetically engineered dermal tissue demonstrates therapeutic activity in mouse model of rheumatoid arthritis","volume":"19","author":"Zafir-Lavie","year":"2017","journal-title":"J. Gene Med."},{"key":"10.1016\/j.jconrel.2018.10.017_bb0125","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0378-1119(91)90434-D","article-title":"Efficient selection for high-expression transfectants with a novel eukaryotic vector","volume":"108","author":"Niwa","year":"1991","journal-title":"Gene"},{"key":"10.1016\/j.jconrel.2018.10.017_bb0130","first-page":"216","article-title":"Preclinical and preliminary clinical evaluation of genetically transduced dermal tissue implants for the sustained secretion of erythropoietin and interferon alpha, human gene therapy","volume":"26","author":"Shapir","year":"2015","journal-title":"Clin. Develop."},{"key":"10.1016\/j.jconrel.2018.10.017_bb0135","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nbt1087","article-title":"Stable antibody expression at therapeutic levels using the 2A peptide","volume":"23","author":"Fang","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2018.10.017_bb0140","first-page":"33","article-title":"Methods for the production of helper-dependent adenoviral vectors, methods in molecular biology (Clifton, N.J.)","volume":"433","author":"Palmer","year":"2008"},{"key":"10.1016\/j.jconrel.2018.10.017_bb0145","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.ymthe.2003.08.014","article-title":"Improved system for helper-dependent adenoviral vector production","volume":"8","author":"Palmer","year":"2003","journal-title":"Mol. Therap."},{"key":"10.1016\/j.jconrel.2018.10.017_bb0150","first-page":"2033","article-title":"Establishing primary adult fibroblast cultures from rodents","author":"Seluanov","year":"2010","journal-title":"J. Visual. Exp."},{"key":"10.1016\/j.jconrel.2018.10.017_bb0155","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ab.2010.07.005","article-title":"Therapeutic antibodies: discovery and development using the ProteOn XPR36 biosensor interaction array system","volume":"406","author":"Bronner","year":"2010","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.jconrel.2018.10.017_bb0160","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1006\/abio.1993.1355","article-title":"Determination of rate and equilibrium binding constants for macromolecular interactions using surface plasmon resonance: use of nonlinear least squares analysis methods","volume":"212","author":"O'Shannessy","year":"1993","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.jconrel.2018.10.017_bb0165","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10549-013-2743-3","article-title":"Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes","volume":"142","author":"Prat","year":"2013","journal-title":"Breast Cancer Res. Treat."},{"issue":"1","key":"10.1016\/j.jconrel.2018.10.017_bb0170","doi-asserted-by":"crossref","DOI":"10.5731\/pdajpst.2018.001105","article-title":"Approval of Ogivri","volume":"72","author":"Rathore","year":"2018","journal-title":"PDA J. Pharm. Sci. Technol."},{"key":"10.1016\/j.jconrel.2018.10.017_bb0175","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.1365-2184.2007.00449.x","article-title":"Differential impact of cetuximab, pertuzumab and trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation","volume":"40","author":"Brockhoff","year":"2007","journal-title":"Cell Prolif."},{"key":"10.1016\/j.jconrel.2018.10.017_bb0180","doi-asserted-by":"crossref","first-page":"e1149","DOI":"10.1038\/cddis.2014.115","article-title":"Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1)","volume":"5","author":"Diessner","year":"2014","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.jconrel.2018.10.017_bb0185","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0002-9440(10)61180-7","article-title":"Breast cancer metastasis to the central nervous system","volume":"167","author":"Weil","year":"2005","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.jconrel.2018.10.017_bb0190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0005233","article-title":"Targeting angiogenesis-dependent calcified neoplasms using combined polymer therapeutics","volume":"4","author":"Segal","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jconrel.2018.10.017_bb0195","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1016\/j.nano.2016.05.016","article-title":"Restoring the oncosuppressor activity of microRNA-34a in glioblastoma using a polyglycerol-based polyplex","volume":"12","author":"Ofek","year":"2016","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2018.10.017_bb0200","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.25281","article-title":"Co-targeting the tumor endothelium and P-selectin-expressing glioblastoma cells leads to a remarkable therapeutic outcome","volume":"6","author":"Ferber","year":"2017","journal-title":"elife"},{"key":"10.1016\/j.jconrel.2018.10.017_bb0205","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gku082","article-title":"S\/MAR sequence confers long-term mitotic stability on non-integrating lentiviral vector episomes without selection","volume":"42","author":"Verghese","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jconrel.2018.10.017_bb0210","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.3892\/mmr.2013.1424","article-title":"Effect of betaglobin MAR characteristic elements on transgene expression","volume":"7","author":"Li","year":"2013","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.jconrel.2018.10.017_bb0215","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0063247","article-title":"Comparison of internal ribosome entry site (IRES) and Furin-2A (F2A) for monoclonal antibody expression level and quality in CHO cells","volume":"8","author":"Ho","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jconrel.2018.10.017_bb0220","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1529-8019.2012.01457.x","article-title":"Biopump: Autologous skin-derived micro-organ genetically engineered to provide sustained continuous secretion of therapeutic proteins","volume":"24","author":"Mitrani","year":"2011","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.jconrel.2018.10.017_bb0225","series-title":"Primary Ear Fibroblast Derivation From Mice, Methods in Molecular Biology (Clifton, N.J.)","first-page":"65","volume":"1031","author":"Moore","year":"2013"},{"key":"10.1016\/j.jconrel.2018.10.017_bb0230","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1200\/JCO.1996.14.3.737","article-title":"Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2\/neu-overexpressing metastatic breast cancer","volume":"14","author":"Baselga","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2018.10.017_bb0235","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3389\/fonc.2012.00062","article-title":"Trastuzumab: updated mechanisms of action and resistance in breast cancer","volume":"2","author":"Vu","year":"2012","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jconrel.2018.10.017_bb0240","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1158\/1535-7163.MCT-07-0079","article-title":"Response to trastuzumab, erlotinib, and bevacizumab, alone and in combination, is correlated with the level of human epidermal growth factor receptor-2 expression in human breast cancer cell lines","volume":"6","author":"Emlet","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jconrel.2018.10.017_bb0245","first-page":"53565","article-title":"Generating primary fibroblast cultures from mouse ear and tail tissues","volume":"107","author":"Khan","year":"2016","journal-title":"J. Visual. Exp."},{"key":"10.1016\/j.jconrel.2018.10.017_bb0250","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1602\/neurorx.2.1.3","article-title":"The blood-brain barrier: bottleneck in brain drug development","volume":"2","author":"Pardridge","year":"2005","journal-title":"NeuroRx"},{"key":"10.1016\/j.jconrel.2018.10.017_bb0255","doi-asserted-by":"crossref","first-page":"84ra43","DOI":"10.1126\/scitranslmed.3002254","article-title":"A therapeutic antibody targeting BACE1 inhibits amyloid-beta production in vivo","volume":"3","author":"Atwal","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2018.10.017_bb0260","first-page":"301","article-title":"Engineering and pharmacology of blood-brain barrier-permeable bispecific antibodies, Advances in pharmacology (San Diego, Calif.)","volume":"71","author":"Stanimirovic","year":"2014"},{"key":"10.1016\/j.jconrel.2018.10.017_bb0265","doi-asserted-by":"crossref","first-page":"261ra154","DOI":"10.1126\/scitranslmed.3009835","article-title":"Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates","volume":"6","author":"Yu","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2018.10.017_bb0270","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1158\/1535-7163.MCT-14-0399","article-title":"ANG4043, a novel brain-penetrant peptide-mAb conjugate, is efficacious against HER2-positive intracranial tumors in mice","volume":"14","author":"Regina","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jconrel.2018.10.017_bb0275","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1046\/j.1471-4159.1996.67020734.x","article-title":"Increased permeability of superoxide dismutase at the blood-nerve and blood-brain barriers with retained enzymatic activity after covalent modification with the naturally occurring polyamine, putrescine","volume":"67","author":"Poduslo","year":"1996","journal-title":"J. Neurochem."},{"key":"10.1016\/j.jconrel.2018.10.017_bb0280","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1046\/j.1471-4159.1996.66041599.x","article-title":"Polyamine modification increases the permeability of proteins at the blood-nerve and blood-brain barriers","volume":"66","author":"Poduslo","year":"1996","journal-title":"J. Neurochem."},{"key":"10.1016\/j.jconrel.2018.10.017_bb0285","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jconrel.2012.09.007","article-title":"Ultrasound-mediated blood-brain\/blood-tumor barrier disruption improves outcomes with trastuzumab in a breast cancer brain metastasis model","volume":"163","author":"Park","year":"2012","journal-title":"J. Control. Rel."},{"key":"10.1016\/j.jconrel.2018.10.017_bb0290","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s40425-015-0084-y","article-title":"Intrathecal trastuzumab: immunotherapy improves the prognosis of leptomeningeal metastases in HER-2+ breast cancer patient","volume":"3","author":"Lu","year":"2015","journal-title":"J. Immunotherap. Cancer"},{"key":"10.1016\/j.jconrel.2018.10.017_bb0295","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1093\/annonc\/mdn654","article-title":"High-dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2 overexpressing breast cancer","volume":"19","author":"Mir","year":"2008","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jconrel.2018.10.017_bb0300","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/archinte.1990.00390130145023","article-title":"Complications associated with Ommaya reservoirs in patients with cancer. The Princess Margaret Hospital experience and a review of the literature","volume":"150","author":"Lishner","year":"1990","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.jconrel.2018.10.017_bb0305","article-title":"Efficacy of humanized CD19-targeted chimeric antigen receptor (CAR)-modified T cells in children with relapsed ALL","volume":"34","author":"Maude","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2018.10.017_bb0310","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","article-title":"Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial","volume":"390","author":"Russell","year":"2017","journal-title":"Lancet (Lond. Engl.)"},{"key":"10.1016\/j.jconrel.2018.10.017_bb0315","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ijpharm.2017.10.002","article-title":"Sustained intrathecal therapeutic protein delivery using genetically transduced tissue implants in a freely moving rat model","volume":"534","author":"Aronson","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2018.10.017_bb0320","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s12264-015-1559-z","article-title":"Effects of fibroblast transplantation into the internal pallidum on levodopa-induced dyskinesias in parkinsonian non-human primates","volume":"31","author":"Singh","year":"2015","journal-title":"Neurosci. Bull."},{"key":"10.1016\/j.jconrel.2018.10.017_bb0325","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1089\/hum.2018.015","article-title":"Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN","volume":"29","author":"Hinderer","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.jconrel.2018.10.017_bb0330","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3389\/fmicb.2011.00201","article-title":"Immunity and AAV-mediated gene therapy for muscular dystrophies in large animal models and human trials","volume":"2","author":"Wang","year":"2011","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.jconrel.2018.10.017_bb0335","series-title":"Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies, Regulatory toxicology and pharmacology","first-page":"164","volume":"Vol. 54","author":"Ponce","year":"2009"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365918305881?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365918305881?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T09:48:03Z","timestamp":1605260883000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365918305881"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":67,"alternative-id":["S0168365918305881"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2018.10.017","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Successful intracranial delivery of trastuzumab by gene-therapy for treatment of HER2-positive breast cancer brain metastases","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2018.10.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}